Company research
LifeMD, Inc.
CIK 948320Updated Sep 24, 2026
Name history
CONVERSION LABS, INC. · through Feb 22, 2021Immudyne, Inc. · through Jun 19, 2018
LFMD price & chart
Loading TradingView…
NASDAQ:LFMD on TradingView ↗About the company
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
In the news
LifeMD to Report Second Quarter 2026 Financial Results on August 5 ↗
LifeMD, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LFMD News provided by DJS Law Group LLP Oct 27, 2025, 03:04 ET Share this article Share to X Share this article Share to X LOS ANGELES , Oct. 27, 2025 /PRNewswire/ -- The DJS Law Group reminds inves ↗
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Oct 27, 2025, 03:02 ET Share this article Share to X Share this article Share to X LOS ANGELES , Oct. 27, 2025 /PRNewswire/ -- The Schall Law Firm , a national ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G - filed by FEDERATED HERMES, INC. regarding LifeMD, Inc.
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
ARS filing
DEFA14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 70,411,319Source | 72,460,026Source | 58,480,709Source | 25,665,853Source |
| Property, Plant and Equipment, NetUSD | 2,444,717Source | 1,479,184Source | 476,303Source | 476,441Source |
| GoodwillUSD | — | — | — | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 35,004,924Source | 33,146,725Source | 3,958,957Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,305,277Source | 8,217,813Source | 5,277,250Source | 2,834,750Source |
| Inventory, NetUSD | 2,773,576Source | 2,797,358Source | 2,759,932Source | 3,703,363Source |
| Assets, CurrentUSD | 51,831,465Source | 48,733,089Source | 42,604,267Source | 11,311,357Source |
| Operating Lease, Right-of-Use AssetUSD | 5,267,857Source | 6,400,596Source | 594,897Source | 1,206,009Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 47,254,739Source | 76,505,394Source | 52,914,550Source | 32,971,356Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 140Source | 140Source | 140Source | 140Source |
| Common Stock, Value, IssuedUSD | 467,600Source | 422,939Source | 383,586Source | 315,528Source |
| Additional Paid in CapitalUSD | 251,455,616Source | 230,508,339Source | 217,550,583Source | 179,015,250Source |
| Retained Earnings (Accumulated Deficit)USD | -228,603,075Source | -236,253,218Source | -214,265,236Source | -190,562,994Source |
| Stockholders' Equity Attributable to ParentUSD | 23,156,580Source | -5,485,501Source | 3,505,372Source | -11,395,777Source |
| Liabilities and EquityUSD | 70,411,319Source | 72,460,026Source | 58,480,709Source | 25,665,853Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 41,573,365Source | 60,255,145Source | 34,781,724Source | 31,374,151Source |
| Operating Lease, Liability, CurrentUSD | 642,422Source | 508,537Source | 603,180Source | 756,093Source |
| Accounts Payable, CurrentUSD | 14,149,154Source | 16,009,484Source | 11,084,855Source | 10,106,793Source |
| Operating Lease, Liability, NoncurrentUSD | 5,681,374Source | 6,265,192Source | 73,849Source | 574,136Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | 1,440,133Source | 2,060,787Source | -475,548Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 15,974,016Source | 20,811,763Source | 13,937,494Source | 12,166,509Source |
| Deferred Revenue, CurrentUSD | 10,807,773Source | 14,480,917Source | 8,828,598Source | — |
| Dividends PayableUSD | 776,563Source | 776,563Source | 776,563Source | 776,563Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 15,619,791Source | -18,728,498Source | -17,839,057Source | -45,021,027Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,496,321Source | 12,234,797Source | 12,489,343Source | 13,734,614Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,150,536Source | 2,940,563Source | 2,442,500Source | 2,192,888Source |
| Increase (Decrease) in InventoriesUSD | -23,782Source | 713,095Source | -405,746Source | 2,183,012Source |
| Increase (Decrease) in Accounts PayableUSD | 3,244,483Source | 4,924,629Source | 978,062Source | 1,251,037Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 354,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 8,280,175Source | 17,513,190Source | 8,820,232Source | -22,935,149Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | 1,012,395Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 6,908,231Source | -11,536,318Source | -8,733,284Source | -13,905,733Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,870,668Source | 1,490,857Source | 203,814Source | 366,633Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 270,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -13,407,012Source | -4,118,673Source | 29,100,820Source | -528,200Source |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,781,394Source | 1,858,199Source | 29,187,768Source | -37,369,082Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 36,786,318Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,461,032Source | 2,528,042Source | 2,148,454Source | 189,000Source |
| Income Taxes Paid, NetUSD | 587,000Source | — | — | — |
| Additional Financial Items | ||||
| Accretion Expense, Including Asset Retirement ObligationsUSD | — | 13,644Source | 167,221Source | 273,822Source |
| Amortization of Intangible AssetsUSD | 94,002Source | 982,405Source | 971,464Source | 926,542Source |
| Capitalized Computer Software, AmortizationUSD | 6,348,932Source | 8,021,141Source | 5,424,810Source | 2,681,807Source |
| DepreciationUSD | 865,524Source | 487,976Source | 203,952Source | 161,885Source |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxUSD | 21,300,000Source | — | — | — |
| Dividends PayableUSD | 776,563Source | 776,563Source | 776,563Source | 776,563Source |
| Gain (Loss) Related to Litigation SettlementUSD | 1,100,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -1,155,851Source | — | -325,198Source | — |
| General and Administrative ExpenseUSD | 57,937,023Source | 72,662,021Source | 51,694,232Source | 46,960,782Source |
| GoodwillUSD | — | — | — | 0Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | 8,862,596Source |
| Goodwill, Impairment LossUSD | — | — | — | 8,000,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | 827,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -10,232,233Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 10,232,233Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 25,852,024Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 24,586,339Source | — | — | — |
| Income Tax Expense (Benefit)USD | 45,721Source | 402,000Source | 428,000Source | 360,700Source |
| Inventory Write-downUSD | — | 675,669Source | 537,685Source | 103,417Source |
| Net Income (Loss) Attributable to ParentUSD | 14,354,106Source | -18,881,732Source | -20,595,992Source | -45,535,659Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 1,265,685Source | 153,234Source | 2,756,935Source | 514,632Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 11,247,856Source | -21,987,982Source | -23,702,242Source | -48,641,909Source |
| Operating ExpensesUSD | 174,010,084Source | 204,530,040Source | 148,135,815Source | 143,813,273Source |
| Operating Lease, ExpenseUSD | 1,500,000Source | 1,200,000Source | 861,000Source | 871,344Source |
| Proceeds from Issuance of Common StockUSD | 8,721,717Source | — | 10,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 5,950Source | 120,312Source | 94,500Source | 90,400Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 194,055,198Source | 212,453,838Source | 152,547,006Source | 119,033,520Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -7,669,694Source | -16,144,681Source | -14,489,273Source | -43,447,781Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -10,186,512Source | -18,326,498Source | -17,411,057Source | -44,660,327Source |
| Income Tax Expense (Benefit)USD | 45,721Source | 402,000Source | 428,000Source | 360,700Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 1,265,685Source | 153,234Source | 2,756,935Source | 514,632Source |
| Net Income (Loss) Attributable to ParentUSD | 14,354,106Source | -18,881,732Source | -20,595,992Source | -45,535,659Source |
| Earnings Per Share, BasicUSD per share | 0.25Source | — | — | — |
| Earnings Per Share, DilutedUSD per share | 0.25Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 45,129,617Source | 41,196,292Source | 33,905,155Source | 30,976,455Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 45,129,617Source | 41,196,292Source | 33,905,155Source | 30,976,455Source |
| Additional Financial Items | ||||
| Accretion Expense, Including Asset Retirement ObligationsUSD | — | 13,644Source | 167,221Source | 273,822Source |
| Amortization of Intangible AssetsUSD | 94,002Source | 982,405Source | 971,464Source | 926,542Source |
| Capitalized Computer Software, AmortizationUSD | 6,348,932Source | 8,021,141Source | 5,424,810Source | 2,681,807Source |
| Gain (Loss) Related to Litigation SettlementUSD | 1,100,000Source | — | — | — |
| General and Administrative ExpenseUSD | 57,937,023Source | 72,662,021Source | 51,694,232Source | 46,960,782Source |
| Goodwill, Impairment LossUSD | — | — | — | 8,000,000Source |
| Gross ProfitUSD | 166,340,390Source | 188,385,359Source | 133,646,542Source | 100,365,492Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -10,232,233Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 10,232,233Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.3Source | -0.53Source | -0.7Source | -1.57Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.3Source | -0.53Source | -0.7Source | -1.57Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 25,852,024Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 24,586,339Source | — | — | — |
| Interest ExpenseUSD | 1,360,967Source | 2,181,817Source | 2,596,586Source | 1,275,946Source |
| Marketing and Advertising ExpenseUSD | 86,100,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 11,247,856Source | -21,987,982Source | -23,702,242Source | -48,641,909Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | -13,338,483Source | — | — | — |
| Operating ExpensesUSD | 174,010,084Source | 204,530,040Source | 148,135,815Source | 143,813,273Source |
| Operating Lease, ExpenseUSD | 1,500,000Source | 1,200,000Source | 861,000Source | 871,344Source |
| Other General ExpenseUSD | 11,073,155Source | 9,118,032Source | 6,297,321Source | 6,717,795Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 3,106,250Source | 3,106,250Source | 3,106,250Source | 3,106,250Source |
| Preferred Stock, Dividends Per Share, DeclaredUSD per share | 2.22Source | 2.22Source | 2.22Source | 2.22Source |
| Selling and Marketing ExpenseUSD | 86,074,473Source | 103,020,025Source | 76,451,466Source | 78,369,430Source |
Filing attachments
ex99-1.htm · 8-K · 2026-09-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 DALLAS, September 15, 2026 AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD Through an exclusive collaboration with LifeMD, eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, a $228 annual value, with on-demand access to a nationwide virtual care and pharmacy platform. Key Takeaways: More than 100 million eligible AT&T wireless and fiber customers will rec…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-05
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end …
Read attachment ↗ex99-1.htm · 8-K · 2026-06-22
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July 2026 in 37 states Companies to collaborate on consumer education and promotional initiatives to expa…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-06
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 LifeMD Reports First Quarter 2026 Results Gross margin increased approximately 420 basis points to 88%, versus the first quarter of 2025, reflecting favorable revenue mix and lower fulfillment costs. Record GLP-1 patient sign-ups, with weight management new-patient revenues growing approximately 120% versus the fourth quarter of 2025. 657% quarter-over-quarter growth in Women’s Health patient signups with approximately 70% reducti…
Read attachment ↗